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ABSTRACT
Objective: The proposed study aimed to develop a stability-indicating ultra-performance liquid chromatography (UPLC) method for the estimation of 
cabozantinib in pharmaceutical dosage form and validate the method in accordance with the International Conference on Harmonization guidelines.
Methods: The optimized conditions for the developed UPLC method are Acquity UPLC Hibar C18 (100 mm × 2.1 mm, 1.7 µ) column maintained at 
30°C with mobile phase consisting of 0.1% orthophosphoric acid and acetonitrile in the ratio of 55:45% v/v on isocratic mode at flow rate of 0.3 mL/
min. The sample was detected at 244 nm.
Results: The retention time for cabozantinib was deemed 1.3 min. The developed method was validated for accuracy, precision, specificity, ruggedness, 
robustness, and solution stability. The method obeyed Beer’s law in the concentration range of 20 µg/mL and 120 µg/mL with correlation coefficient 
of 0.9997. Forced degradation studies were conducted by exposing the drug solution to numerous stress conditions such as acidic, basic, peroxide, 
neutral, photolytic, and thermal conditions. The net degradation was considered within the limits, indicating that drug is stable in stressed conditions.
Conclusion: The developed method for the estimation of cabozantinib can be utilized for the routine analysis of pharmaceutical dosage form.
Keywords: Cabozantinib, Stability indicating, Method development, Validation, Ultra-performance liquid chromatography.
INTRODUCTION
Cabozantinib (Fig. 1) [1-5] chemically defined as N-(4-(6,7-
dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-
1,1-dicarboxamide, (2S)-hydroxybutanedioate. It is white to off-white 
solid, practically insoluble in aqueous media. It has pKa values of 5.9 and 
13.46. It belongs to anticancer category which acts by inhibiting tyrosine 
kinase activity of receptors that participate in pathologic processes 
such as oncogenesis, metastasis, tumor angiogenesis, and maintenance 
of tumor microenvironment. It is used in the treatment of medullary 
thyroid cancer and a second-line treatment for renal cell carcinoma.
Ultra-performance liquid chromatography (UPLC) [6] is specially 
designed to withstand higher system pressure during chromatographic 
analysis so that it enables a significant decrease in separation time 
and solvent consumption. UPLC columns packed with 1.7 μm sized 
particles provide not only increased efficiency but also the ability to 
work at an increased linear velocity without loss of efficiency, providing 
both resolution and speed. Using advantages of UPLC, a number of 
applications in different fields including pharmacy, clinical analysis, and 
pesticide analysis have been recorded.
The literature survey reveals that there are only few methods developed 
for the estimation of cabozantinib using LC coupled with tandem 
mass spectrometry method (LC–MS/MS) [7,8], spectrofluorimetric 
method [9] and UPLC coupled with tandem mass spectrometry method 
(UPLC–MS/MS)[10].
As there was no method developed using UPLC, the present study 
aimed to develop and validate a UPLC stability-indicating method for 
the estimation of cabozantinib in pharmaceutical dosage form.
METHODS
Reagents and chemicals
Cabozantinib working standard was procured from Spectrum 
Labs, Hyderabad, as a gift sample. The Cometriq capsules were 
purchased from a local pharmacy. All the chemicals used were of 
AR grade purchased from Merck, Mumbai. All the solvents used 
were of high-performance LC grade purchased from Sigma-Aldrich, 
Mumbai.
Chromatographic conditions and instruments
The ACQUITY UPLC [11] system equipped with binary solvent manager, 
sample manager, ultraviolet (UV) detector, and Hibar C18 (100 mm × 
2.1 mm, 1.7 µ) column was used for the determination of cabozantinib. 
The optimized conditions included 0.1% orthophosphoric acid and 
acetonitrile (55:45%v/v) as mobile phase run on an isocratic mode at 
a flow rate of 0.3 mL/min. The column was held at 30°C and detection 
was done at 244 nm. Further, equipment included pH meter, ultrasonic 
bath sonicator, and weighing balance.
Preparation of mobile phase
Mixture of 0.1% orthophosphoric acid and acetonitrile in the ratio of 
55:45% v/v was used as mobile phase.
Preparation of standard and sample solutions
About 80 mg of cabozantinib working standard was dissolved in 100 mL 
of diluent. Then, 1 mL of the above stock solution was diluted to 10 mL 
using diluent to get a concentration of 80 µg/mL.
20 capsules (Cometriq) were weighed accurately and average weight 
was calculated. An amount equivalent to 80 mg of the drug was 
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dissolved in 100 mL of diluent, filtered the solution, and diluted 1 mL of 
the above solution to 10 mL with diluent.
Method validation
The developed method was validated in accordance with the 
International Conference on Harmonization (ICH) guidelines [12,13].
Specificity
The specificity of the method was determined by comparing the drug 
solution to the placebo solution and observed for the interference of 
placebo peak with drug peak.
Accuracy
Accuracy of the method was determined in accordance with percentage 
recovery. The drug solution along with sample was prepared in three 
concentration levels, i.e. 50%, 100%, and 150%. Then, the percentage 
recovery was calculated.
Precision
Precision of the method was established by injecting the standard 
solution 6 times into the UPLC system and percentage relative standard 
deviation (RSD) was calculated.
Linearity
Linearity of the method was determined by preparing a series of 
dilutions ranging from 20 µg/mL to 120 µg/mL and injecting them into 
UPLC system.
Ruggedness
Ruggedness was determined by injecting the standard solution into 
UPLC 6 times for different days. The percentage RSD was calculated.
Robustness
Robustness of the method was determined by varying the optimized 
analytical conditions such as mobile phase composition by ±5%, flow 
rate by ±0.1 mL/min, and column oven temperature by ±5°C.
Solution stability
Solution stability determined on the basis of analyzing the standard 
drug solution after storage for 24 h under laboratory conditions.
Forced degradation studies
Forced degradation studies [14,15] were carried out for drug by 
exposing the drug solution to the various stress conditions such as 
acidic (2 N hydrochloric acid for 30 min at 60°C), basic (2 N sodium 
hydroxide for 30 min at 60°C), peroxide (20% hydrogen peroxide [H2O2] 
for 30 min at 60°C), neutral (refluxing the drug in water for 6 h at 60°C), 
photolytic (105°C for 6 h), and thermal (exposing the drug solution to 
UV light by keeping the beaker in UV chamber for 7 day or 200 Wt h/m2 
in photostability chamber) conditions.
RESULTS
From the UV spectrum, detection wavelength for Cabozantinib was 
found to be 244nm.
DISCUSSION
For the development of a method for the estimation of cabozantinib in 
pharmaceutical dosage form, initially, many mobile phases and many 
columns were tried to elute the drug peak with less tailing factor and 
more plate count. Acquity UPLC Hibar C18 (100 mm × 2.1 mm, 1.7 µ) 
column and 0.1% OPA:acetonitrile (55:45% v/v) as mobile phase were 
selected based on peak parameters. The detection wavelength was 
found to be 244 nm as shown in Fig. 2 of the UV spectrum.
Prepared standard solution, sample solution, and the blank solution 
were injected into the UPLC system, and system suitability parameters 
were noted as summarized in Table 1 along with chromatograms as 
showed in Fig. 3a-c, respectively.
The developed method was identified to obey Beer’s law in the 
concentration range of 20 µg/mL–120 µg/mL with correlation coefficient 
of 0.9997. A linearity graph was plotted between concentration and 
peak area as showed in Fig. 4 and results as presented in Table 1.
The method was found to be accurate as the percentage recovery was 
99.57–99.91% and was within the limits. The percentage RSD was 
determined to be 0.3, which indicates that the method was precise. The 
method was shown to be specific, as there is no interference of retention 
time of placebo peak with that of drug peak. The placebo chromatogram 
was displayed in Fig. 5.
Forced degradation studies results indicate that the drug was reported 
to be stable in various stress conditions as net degradation was found to 
Fig. 1: Chemical structure of cabozantinib
Fig. 2: Ultraviolet spectrum of cabozantinib
Table 1: System suitability and validation parameter results
Parameter Result Result
Precision (%RSD, n) 0.3
Accuracy (% recovery, n) 99.57–99.91% 
Specificity Specific, no 
interference
Linearity range (µg/mL) 20–120
Correlation coefficient, r 0.9997
Limit of detection (µg/mL) 0.15
Limit of quantitation (µg/mL) 0.47
Ruggedness (%RSD, n) Day 1 Day 2
0.5 0.3












Solution stability (%RSD, n)
USP plate count
USP tailing factor





n: Number of samples, i.e., 6 samples, %RSD: % Relative standard deviation
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be within the limits. The chromatograms were illustrated in Fig. 6 and 
results were outlined in Table 2.
CONCLUSION
A specific, accurate, and precise stability-indicating method was 
developed for the estimation of cabozantinib in pharmaceutical dosage 
form using UPLC. The method was validated using numerous validation 
parameters, and the method was found to be linear, precise, accurate, 
specific, and robust. From the degradation studies conducted, it infers 
that cabozantinib was more stable at more concentrations of acid, base, 
peroxide, thermal, UV, and water stress study conditions. The run time 
was 3 min which enables rapid quantitation of many samples in routine 
and quality control analysis of capsule formulation.
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Fig. 4: Linearity plot of cabozantinib
Fig. 5: Ultra-performance liquid chromatography chromatogram 
of placebo solution
Table 2: Forced degradation studies results
Stress 
condition
% assay % area of 
degradation peak
% degradation
2 N HCl for 
30 min at 60°C
97.69 0.08 2.31
2 N NaOH for 
30 min at 60°C
96.87 0.02 3.13
20% H2O2 for 
30 min at 60°C
98.26 - 1.74
Water for 6 h 
at 60°C
99.45 - 0.55
UV light 200 
Wts/h or 7 day
99.05 - 0.95
105°C for 6 h 98.70 - 1.30
Fig. 3: (a) Ultra-performance liquid chromatography (UPLC) chromatogram of a standard solution, (b) UPLC chromatogram of sample 
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Fig. 6: (a) Acid degradation ultra-performance liquid chromatography (UPLC) chromatogram, (b) base degradation UPLC chromatogram, 
(c) peroxide degradation UPLC chromatogram, (d) water stress study UPLC chromatogram, (e) photostability degradation UPLC 
chromatogram, (f) dry heat study UPLC chromatogram
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